1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Prostate Cancer Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Prostate Cancer Market Revenue and Volume, by Drug Class
8.1.1. Hormonal ADT
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. AR-Directed Therapies
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Cytotoxic agents
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Bone metastases
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. therapeutic vaccines
8.1.5.1. Market Revenue and Volume Forecast
8.1.6. PARP inhibitors
8.1.6.1. Market Revenue and Volume Forecast
8.1.7. Kinase inhibitors
8.1.7.1. Market Revenue and Volume Forecast
8.1.8. PSMA-targeted radioligands
8.1.8.1. Market Revenue and Volume Forecast
9.1. Prostate Cancer Market Revenue and Volume, by Distribution Channel
9.1.1. Hospital Pharmacies
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Drug store & Retail pharmacies
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Online pharmacies
9.1.3.1. Market Revenue and Volume Forecast
10.1. North America
10.1.1. Market Revenue and Volume Forecast, by Drug Class
10.1.2. Market Revenue and Volume Forecast, by Distribution Channel
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, by Drug Class
10.1.3.2. Market Revenue and Volume Forecast, by Distribution Channel
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, by Drug Class
10.1.4.2. Market Revenue and Volume Forecast, by Distribution Channel
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, by Drug Class
10.2.2. Market Revenue and Volume Forecast, by Distribution Channel
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, by Drug Class
10.2.3.2. Market Revenue and Volume Forecast, by Distribution Channel
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, by Drug Class
10.2.4.2. Market Revenue and Volume Forecast, by Distribution Channel
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, by Drug Class
10.2.5.2. Market Revenue and Volume Forecast, by Distribution Channel
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, by Drug Class
10.2.6.2. Market Revenue and Volume Forecast, by Distribution Channel
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, by Drug Class
10.3.2. Market Revenue and Volume Forecast, by Distribution Channel
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, by Drug Class
10.3.3.2. Market Revenue and Volume Forecast, by Distribution Channel
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, by Drug Class
10.3.4.2. Market Revenue and Volume Forecast, by Distribution Channel
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, by Drug Class
10.3.5.2. Market Revenue and Volume Forecast, by Distribution Channel
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, by Drug Class
10.3.6.2. Market Revenue and Volume Forecast, by Distribution Channel
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, by Drug Class
10.4.2. Market Revenue and Volume Forecast, by Distribution Channel
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, by Drug Class
10.4.3.2. Market Revenue and Volume Forecast, by Distribution Channel
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, by Drug Class
10.4.4.2. Market Revenue and Volume Forecast, by Distribution Channel
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, by Drug Class
10.4.5.2. Market Revenue and Volume Forecast, by Distribution Channel
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, by Drug Class
10.4.6.2. Market Revenue and Volume Forecast, by Distribution Channel
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, by Drug Class
10.5.2. Market Revenue and Volume Forecast, by Distribution Channel
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, by Drug Class
10.5.3.2. Market Revenue and Volume Forecast, by Distribution Channel
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, by Drug Class
10.5.4.2. Market Revenue and Volume Forecast, by Distribution Channel
11.1. AbbVie, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Astellas Pharma, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. AstraZeneca p
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Bayer AG
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Clovis Oncology, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Dendreon Pharmaceuticals LLC
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Ferring Pharmaceuticals
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Johnson & Johnson (Janssen)
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Merck & Co., Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Pfizer, Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
